Cosmetic cross-reference

Potassium Gluconate

CAS 299-27-4

Potassium Gluconate (CAS 299-27-4) is a Phase 1 pharmaceutical compound with 0 bioactivity targets and 301 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
301
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Potassium Gluconate
CAS Number
299-27-4
UNII
12H3K5QKN9
InChIKey
HLCFGWHYROZGBI-JJKGCWMISA-M
ChEMBL ID
CHEMBL2106978
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 1
Early-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL2106978 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 26 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Blood creatine increased 36 129.241 10005464
Toxic epidermal necrolysis 51 126.214 10044223
Dehydration 57 52.086 10012174
Cafe au lait spots 8 40.072 10006926
Wolff-Parkinson-White syndrome 8 36.067 10048015
Kidney duplex 8 35.513 10023416
Ear malformation 8 33.898 10014016
Anal stenosis 8 33.725 10002176
Phimosis 8 33.122 10034878
Pyelocaliectasis 9 32.669 10061927
Dacryostenosis acquired 8 32.537 10053990
Motor developmental delay 8 32.425 10070302
Pulmonary valve stenosis 8 32.363 10037450
Sepsis neonatal 8 31.661 10040049
Foetal distress syndrome 9 28.654 10016855
Cryptorchism 8 27.74 10011498
Developmental hip dysplasia 8 27.642 10073767
Speech disorder developmental 8 25.223 10041467
Diarrhoea 88 24.232 10012735
Anaemia 55 24.128 10002034
Klebsiella sepsis 8 23.934 10054160
Pneumonia 71 23.262 10035664
Posture abnormal 8 22.8 10036436
Haemangioma 8 22.378 10018814
Blood potassium decreased 17 21.463 10005724
Overweight 8 21.335 10033307

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
POTASSIUM GLUCONATE 89903 SU MTHSPL
potassium gluconate 89903 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Potassium Gluconate used for in pharmaceutical contexts?

Potassium Gluconate (CAS 299-27-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Potassium Gluconate?

Potassium Gluconate has 301 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Blood creatine increased, Toxic epidermal necrolysis, Dehydration, Cafe au lait spots, Wolff-Parkinson-White syndrome. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Potassium Gluconate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Potassium Gluconate with EU status "permitted".

What clinical phase is Potassium Gluconate in?

Potassium Gluconate is rendered with ChEMBL max phase 1.